Connect with us

Press Release

PayYoda analyzing the Blockchain payment characteristics and putting forward the Blockchain payment security reference

Published

on

The industrial circle and academic circle have begun to realize the importance and value of Blockchain payment security, and have carried out active exploration now. However, the current Blockchain payment is still in the early stage of industrial development with systematic study lacked. PayYoda analyzes the Blockchain payment security demand characteristics and defines the Blockchain payment security boundary, laying the foundation of Blockchain payment security reference frame.

Blockchain payment problem: Serious security privacy problem and lack of trust between both parties of the transaction

The traditional payment way is always of high risk, poor efficiency and many restrictions. Especially for the international trade, the buyer shall transfer money to the supplier’s account which needs to be confirmed by many international banks midway with complicated formalities and a long time taken (varying from several days to ten days and a half months) after a deal is closed. More importantly, the account is often frozen for no reason and the high service charge needs to be paid in the whole process because all countries have strict regulations on the amount and types of transactions when international payment. Furthermore, the centralized settlement system is with non-transparent data and unsafe hidden dangers, so the personal information may be disclosed.

Based on the problem, PayYoda puts forward the solution:

I. Credit-driven ecosystem

PayYoda constructs the credit-driven ecosystem by the credit scoring system to solve the security payment problem. Various payment security accidents (including merchant fraud, malicious user attack, phishing site and privacy disclosure) happen to the online payment and offline payment. How to create a safe payment environment becomes the high-priority tasks of all the payment networks.

The PayYoda ecosphere is credit-driven. To achieve the goal, related measures (including credit-driven ecology, merchant caution money, safety fund, privacy protection, credit score, and decentralized risk control anti-fraud) shall be taken to ensure the user asset security in many fields thoroughly.

II. Publicity, transparency and traceability

In addition to this, PayYoda’s strategy is solving the data source and data trust problems by its hardware equipment with machine language, and ensuring the data authenticity of the whole chain based on Blockchain characteristics-decentralization and immutability. The PayYoda’s design ensures the payment transaction data security in the process of acquisition, transmission, storage and computation with stable and reliable technology platform provided for data transmission and value circulation on the digital asset trading.

III. Decentralizing the payment on the Blockchain

After PayYoda implements the actual scenario of digital currency and realizes the integration with payment transactions via Blockchain, it won’t rely on the system in the central position for fund clearing and trading information storage any longer, but can transfer the value directly based on consensus mechanism which doesn’t need any trust coordination. The mechanism transformation result is as follows: On one hand, the huge service cost and maintenance costs of the third party of the third party institution are saved, the business process is simplified and the business costs for banks and customers are lowered; On the other hand, the flattening of the process increases the transfer speed and realizes the real-time transfer, and the security of the whole system can be ensured even though multiple nodes are attacked because a complete set of data copies is stored at each node of the system.

IV. Secure trading system based on artificial intelligence

The PayYoda secure trading protection system is based on multi-core concurrent technology, integrated safety engine technology, zero-copy technique, and other high performance architectures. It integrates ten layers of fine filtering function based on data header and data content (including DOS defense, user authentication, application control, intrusion prevention, site classification and filtering, virus filtration, web application defense and data leak prevention), forms the integrated security defense system from the network layer to the application layer, and realizes the clean flow delivery.

On the basis of artificial intelligence, PayYoda provides such abilities as data analysis, knowledge extraction, independent study, intelligent decision and automatic control which can create the innovative applications in the fields of network information security (such as network protection, data management, message audit, intelligent security and financial risk control).

V. Construction of sustainable payment ecosystem

The sustainable evolution of the platform (as the basic payment network) is of great importance. And the continuous evolution of the platform happens due to sustainable innovation ability in the premise of abiding by common rules. The common rules of the platform are ensured by the governance mechanism and consensus mechanism. As for the innovation, the development history of e-payment in these decades clearly shows: As long as the power is given to the innovators closest to the market, there will always be an endless supply of ideas. In terms of governance mechanism, PayYoda adopts the fully open ecological model so that the ecosphere participants can focus on the tasks they are best at and maximize their respective profits by the corresponding incentive mechanism with innovation driven via the market end.

PayYoda will continue to be rooted in the Blockchain-fertile soil and cooperate with various financial institutions and entity industries to build the decentralized payment ecology together based on Blockchain in the future!

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot

Published

on

Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.

AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.

The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“

Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.

“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“

The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.

Media Contact

Company: AI Labs

Contact: Media Team

Email: ryan@academic-labs.org

Website: https://ai-labs.live/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

Published

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.

 

The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.

 

The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.

 

Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.

 

Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.

 

Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.

 

More Information About Povorcitinib Phosphate Tablets

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.

 

A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).

 

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

 

Reference

1、China Insights Consultancy (CIC) report

2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

Published

on

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST